{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:34:04Z","timestamp":1777905244067,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00213-024-06603-y","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T06:01:51Z","timestamp":1715407311000},"page":"1883-1894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis"],"prefix":"10.1007","volume":"241","author":[{"given":"Matan","family":"Avrahami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1041-9142","authenticated-orcid":false,"given":"Timur","family":"Liwinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafrir","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Peskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polina","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sarlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Undine E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Amital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"6603_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.159.1.1","volume":"159","author":"American Psychiatric Association","year":"2002","unstructured":"American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1\u201350","journal-title":"Am J Psychiatry"},{"key":"6603_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/YIC.0000000000000084","volume":"30","author":"M Amitai","year":"2015","unstructured":"Amitai M, Sachs E, Zivony A et al (2015) Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients. Int Clin Psychopharmacol 30:241\u2013248. https:\/\/doi.org\/10.1097\/YIC.0000000000000084","journal-title":"Int Clin Psychopharmacol"},{"key":"6603_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/09540260902962206","volume":"21","author":"M Atmaca","year":"2009","unstructured":"Atmaca M (2009) Valproate and neuroprotective effects for bipolar disorder. Int Rev Psychiatry 21:410\u2013413. https:\/\/doi.org\/10.1080\/09540260902962206","journal-title":"Int Rev Psychiatry"},{"key":"6603_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2165\/00023210-200721120-00005","volume":"21","author":"JM Azorin","year":"2007","unstructured":"Azorin JM, Findling RL (2007) Valproate Use in Children and adolescents with bipolar disorder. CNS Drugs 21:1019\u20131033. https:\/\/doi.org\/10.2165\/00023210-200721120-00005","journal-title":"CNS Drugs"},{"key":"6603_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","volume":"126","author":"L Baandrup","year":"2020","unstructured":"Baandrup L (2020) Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol 126:183\u2013192. https:\/\/doi.org\/10.1111\/bcpt.13384","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6603_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/archpsyc.57.2.187","volume":"57","author":"RJ Baldessarini","year":"2000","unstructured":"Baldessarini RJ, Tondo L (2000) Does Lithium Treatment still work? Arch Gen Psychiatry 57:187. https:\/\/doi.org\/10.1001\/archpsyc.57.2.187","journal-title":"Arch Gen Psychiatry"},{"key":"6603_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1192\/apt.bp.107.004184","volume":"13","author":"DS Baldwin","year":"2007","unstructured":"Baldwin DS, Kosky N (2007) Off-label prescribing in psychiatric practice. Adv Psychiatr Treat 13:414\u2013422. https:\/\/doi.org\/10.1192\/apt.bp.107.004184","journal-title":"Adv Psychiatr Treat"},{"key":"6603_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","volume":"26","author":"J Ballon","year":"2013","unstructured":"Ballon J, Stroup TS (2013) Polypharmacy for schizophrenia. Curr Opin Psychiatry 26:208\u2013213. https:\/\/doi.org\/10.1097\/YCO.0b013e32835d9efb","journal-title":"Curr Opin Psychiatry"},{"key":"6603_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TRE Barnes","year":"2011","unstructured":"Barnes TRE, Paton C (2011) Antipsychotic polypharmacy in Schizophrenia. CNS Drugs 25:383\u2013399. https:\/\/doi.org\/10.2165\/11587810-000000000-00000","journal-title":"CNS Drugs"},{"key":"6603_CR10","volume-title":"Applied Clinical Pharmacokinetics","author":"LA Bauer","year":"2014","unstructured":"Bauer LA (2014) Applied Clinical Pharmacokinetics, 3rd edn. McGraw-Hill Education, New York","edition":"3"},{"key":"6603_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2710.1993.tb00612.x","volume":"18","author":"MJG Bellver","year":"1993","unstructured":"Bellver MJG, S\u00e1nchez MJG, Gonzalez ACA et al (1993) Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther 18:191\u2013197. https:\/\/doi.org\/10.1111\/j.1365-2710.1993.tb00612.x","journal-title":"J Clin Pharm Ther"},{"key":"6603_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2165\/00023210-200721090-00005","volume":"21","author":"M Bialer","year":"2007","unstructured":"Bialer M (2007) Extended-release formulations for the treatment of Epilepsy. CNS Drugs 21:765\u2013774. https:\/\/doi.org\/10.2165\/00023210-200721090-00005","journal-title":"CNS Drugs"},{"key":"6603_CR13","doi-asserted-by":"crossref","unstructured":"Birkett DJ (1994) Pharmacokinetics made easy 9: non-linear pharmacokinetics. Aust Prescr 17","DOI":"10.18773\/austprescr.1994.046"},{"key":"6603_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(sici)1099-081x(199907)20:5<233::aid-bdd179>3.0.co;2-5","volume":"20","author":"B Blanco-Serrano","year":"1999","unstructured":"Blanco-Serrano B, Otero MJ, Santos-Buelga D et al (1999) Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 20:233\u2013240. https:\/\/doi.org\/10.1002\/(sici)1099-081x(199907)20:5%3C233::aid-bdd179%3E3.0.co;2-5","journal-title":"Biopharm Drug Dispos"},{"key":"6603_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s002280050199","volume":"51","author":"V Br\u00e9ant","year":"1996","unstructured":"Br\u00e9ant V, Charpiat B, Sab JM et al (1996) How many patients and blood levels are necessary for population pharmacokinetic analysis? Eur J Clin Pharmacol 51:283\u2013288. https:\/\/doi.org\/10.1007\/s002280050199","journal-title":"Eur J Clin Pharmacol"},{"key":"6603_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2125.1983.tb02151.x","volume":"16","author":"S Bryson","year":"1983","unstructured":"Bryson S, Verma N, Scott P, Rubin P (1983) Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol 16:104\u2013105. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02151.x","journal-title":"Br J Clin Pharmacol"},{"key":"6603_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/sj.npp.1300023","volume":"28","author":"DE Casey","year":"2003","unstructured":"Casey DE, Daniel DG, Wassef AA et al (2003) Effect of Divalproex combined with olanzapine or risperidone in patients with an Acute Exacerbation of Schizophrenia. Neuropsychopharmacology 28:182\u2013192. https:\/\/doi.org\/10.1038\/sj.npp.1300023","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 2","key":"6603_CR18","first-page":"74","volume":"37","author":"L Citrome","year":"2003","unstructured":"Citrome L (2003) Schizophrenia and valproate. Psychopharmacol Bull 37(Suppl 2):74\u201388","journal-title":"Psychopharmacol Bull"},{"key":"6603_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/clpt.1993.5","volume":"53","author":"JC Cloyd","year":"1993","unstructured":"Cloyd JC, Fischer JH, Kriel RL, Kraus DM (1993) Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 53:22\u201329. https:\/\/doi.org\/10.1038\/clpt.1993.5","journal-title":"Clin Pharmacol Ther"},{"key":"6603_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bdd.636","volume":"29","author":"T Correa","year":"2008","unstructured":"Correa T, Rodr\u00edguez I, Romano S (2008) Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos 29:511\u2013520. https:\/\/doi.org\/10.1002\/bdd.636","journal-title":"Biopharm Drug Dispos"},{"key":"6603_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","volume":"59","author":"EL Desoky","year":"2004","unstructured":"Desoky EL, Fuseau ES, Din Amry EEL, Cosson S V (2004) Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol 59:783\u2013790. https:\/\/doi.org\/10.1007\/s00228-003-0699-7","journal-title":"Eur J Clin Pharmacol"},{"key":"6603_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2125.1981.tb01273.x","volume":"12","author":"S Dhillon","year":"1981","unstructured":"Dhillon S, Richens A (1981) Serum protein binding of diazepam and its displacement by valproic acid in vitro [letter]. Br J Clin Pharmacol 12:591\u2013592. https:\/\/doi.org\/10.1111\/j.1365-2125.1981.tb01273.x","journal-title":"Br J Clin Pharmacol"},{"key":"6603_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2125.1982.tb01421.x","volume":"13","author":"S Dhillon","year":"1982","unstructured":"Dhillon S, Richens A (1982) Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol 13:553\u2013560. https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb01421.x","journal-title":"Br J Clin Pharmacol"},{"key":"6603_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W et al (2015) A Population Pharmacokinetic Model of Valproic Acid in Pediatric patients with Epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54:305\u2013317. https:\/\/doi.org\/10.1007\/s40262-014-0212-8","journal-title":"Clin Pharmacokinet"},{"key":"6603_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/BF02353461","volume":"23","author":"EI Ette","year":"1995","unstructured":"Ette EI, Kelman AW, Howie CA, Whiting B (1995) Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm 23:551\u2013566. https:\/\/doi.org\/10.1007\/BF02353461","journal-title":"J Pharmacokinet Biopharm"},{"key":"6603_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1192\/pb.27.12.446","volume":"27","author":"C Fisher","year":"2003","unstructured":"Fisher C, Broderick W (2003) Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder? Psychiatr Bull 27:446\u2013448. https:\/\/doi.org\/10.1192\/pb.27.12.446","journal-title":"Psychiatr Bull"},{"key":"6603_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.wnf.0000154221.37887.73","volume":"28","author":"J Fleming","year":"2005","unstructured":"Fleming J, Chetty M (2005) Psychotropic drug interactions with Valproate. Clin Neuropharmacol 28:96\u2013101. https:\/\/doi.org\/10.1097\/01.wnf.0000154221.37887.73","journal-title":"Clin Neuropharmacol"},{"key":"6603_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jad.2007.03.003","volume":"104","author":"J Garnham","year":"2007","unstructured":"Garnham J, Munro A, Slaney C et al (2007) Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 104:185\u2013190. https:\/\/doi.org\/10.1016\/j.jad.2007.03.003","journal-title":"J Affect Disord"},{"key":"6603_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2146\/ajhp140191","volume":"72","author":"HG Gibbs","year":"2015","unstructured":"Gibbs HG, Zimmerman DE, Shermock KM et al (2015) Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients. Am J Health-System Pharm 72:121\u2013126. https:\/\/doi.org\/10.2146\/ajhp140191","journal-title":"Am J Health-System Pharm"},{"key":"6603_CR30","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1007\/BF01371006","volume":"19","author":"TH Grasela","year":"1991","unstructured":"Grasela TH, Sheiner LB (1991) Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 19:S25\u2013S36. https:\/\/doi.org\/10.1007\/BF01371006","journal-title":"J Pharmacokinet Biopharm"},{"key":"6603_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","volume":"5","author":"R Gugler","year":"1980","unstructured":"Gugler R, von Unruh GE (1980) Clinical pharmacokinetics of valproic Acid1. Clin Pharmacokinet 5:67\u201383. https:\/\/doi.org\/10.2165\/00003088-198005010-00002","journal-title":"Clin Pharmacokinet"},{"key":"6603_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1742-7843.2007.00061.x","volume":"100","author":"A Gunes","year":"2007","unstructured":"Gunes A, Bilir E, Zengil H et al (2007) Inhibitory effect of Valproic Acid on Cytochrome P450 2C9 activity in Epilepsy patients. Basic Clin Pharmacol Toxicol 100:383\u2013386. https:\/\/doi.org\/10.1111\/j.1742-7843.2007.00061.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6603_CR33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1517\/17425250902911455","volume":"5","author":"PM Haddad","year":"2009","unstructured":"Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5:539\u2013551. https:\/\/doi.org\/10.1517\/17425250902911455","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"6603_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/01621459.1987.10478440","volume":"82","author":"T Hastie","year":"1987","unstructured":"Hastie T, Tibshirani R (1987) Generalized additive-models - some applications. J Am Stat Assoc 82:371\u2013386","journal-title":"J Am Stat Assoc"},{"key":"6603_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement H et al (2018) Consensus guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51:9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"6603_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/ph14030204","volume":"14","author":"T Iannaccone","year":"2021","unstructured":"Iannaccone T, Sellitto C, Manzo V et al (2021) Pharmacogenetics of Carbamazepine and Valproate: focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals 14:204. https:\/\/doi.org\/10.3390\/ph14030204","journal-title":"Pharmaceuticals"},{"key":"6603_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1358\/mf.2007.29.10.1116313","volume":"29","author":"SM Jankovic","year":"2007","unstructured":"Jankovic SM, Milovanovic JR (2007) Pharmacokinetic modelling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol 29:673. https:\/\/doi.org\/10.1358\/mf.2007.29.10.1116313","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"6603_CR38","first-page":"1576","volume":"25","author":"D Jiang","year":"2004","unstructured":"Jiang D, Wang L (2004) Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. Acta Pharmacol Sin 25:1576\u20131583","journal-title":"Acta Pharmacol Sin"},{"key":"6603_CR39","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","volume":"28","author":"D Jiang","year":"2007","unstructured":"Jiang D, Wang L, Wang Y et al (2007) Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin 28:1677\u20131684. https:\/\/doi.org\/10.1111\/j.1745-7254.2007.00704.x","journal-title":"Acta Pharmacol Sin"},{"key":"6603_CR40","unstructured":"Joint Formulary Committee (2012) British national formulary. Pharmaceutical"},{"key":"6603_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF02353491","volume":"24","author":"EN Jonsson","year":"1996","unstructured":"Jonsson EN, Wade JR, Karlsson MO (1996) Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 24:245\u2013263. https:\/\/doi.org\/10.1007\/BF02353491","journal-title":"J Pharmacokinet Biopharm"},{"key":"6603_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","volume":"24","author":"J-S Kang","year":"2009","unstructured":"Kang J-S, Lee M-H (2009) Overview of Therapeutic Drug Monitoring. Korean J Intern Med 24:1. https:\/\/doi.org\/10.3904\/kjim.2009.24.1.1","journal-title":"Korean J Intern Med"},{"key":"6603_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/epi4.12228","volume":"3","author":"L Karlsson Lind","year":"2018","unstructured":"Karlsson Lind L, Komen J, Wettermark B et al (2018) Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions. Epilepsia Open 3:357\u2013363. https:\/\/doi.org\/10.1002\/epi4.12228","journal-title":"Epilepsia Open"},{"key":"6603_CR44","first-page":"223","volume":"23","author":"D Kennedy","year":"1998","unstructured":"Kennedy D, Koren G (1998) Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci 23:223\u2013228","journal-title":"J Psychiatry Neurosci"},{"key":"6603_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1034\/j.1600-0773.2002.900304.x","volume":"90","author":"T Kondo","year":"2002","unstructured":"Kondo T, Tokinaga N, Suzuki A et al (2002) Altered pharmacokinetics and Metabolism of Valproate after replacement of Conventional Valproate with the slow-release formulation in epileptic patients. Pharmacol Toxicol 90:135\u2013138. https:\/\/doi.org\/10.1034\/j.1600-0773.2002.900304.x","journal-title":"Pharmacol Toxicol"},{"key":"6603_CR46","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/cap.2014.0166","volume":"25","author":"RA Kowatch","year":"2015","unstructured":"Kowatch RA, Scheffer RE, Monroe E et al (2015) Placebo-controlled trial of Valproic Acid Versus Risperidone in Children 3\u20137 years of age with bipolar I disorder. J Child Adolesc Psychopharmacol 25:306\u2013313. https:\/\/doi.org\/10.1089\/cap.2014.0166","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"6603_CR47","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","volume":"61","author":"K Lin","year":"2022","unstructured":"Lin K, Cao VFS, Au C, Dahri K (2022) Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet 61:1345\u20131363. https:\/\/doi.org\/10.1007\/s40262-022-01171-w","journal-title":"Clin Pharmacokinet"},{"key":"6603_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3109\/03602532.2015.1135941","volume":"48","author":"P Matalov\u00e1","year":"2016","unstructured":"Matalov\u00e1 P, Urb\u00e1nek K, Anzenbacher P (2016) Specific features of pharmacokinetics in children. Drug Metab Rev 48:70\u201379. https:\/\/doi.org\/10.3109\/03602532.2015.1135941","journal-title":"Drug Metab Rev"},{"key":"6603_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00007691-198512000-00004","volume":"7","author":"T May","year":"1985","unstructured":"May T, Rambeck B (1985) Serum concentrations of Valproic Acid. Ther Drug Monit 7:387\u2013390. https:\/\/doi.org\/10.1097\/00007691-198512000-00004","journal-title":"Ther Drug Monit"},{"key":"6603_CR51","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clinthera.2017.04.005","volume":"39","author":"J Methaneethorn","year":"2017","unstructured":"Methaneethorn J (2017) Population Pharmacokinetics of Valproic Acid in patients with Mania: implication for individualized dosing regimens. Clin Ther 39:1171\u20131181. https:\/\/doi.org\/10.1016\/j.clinthera.2017.04.005","journal-title":"Clin Ther"},{"key":"6603_CR50","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J (2018) A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol 84:816\u2013834. https:\/\/doi.org\/10.1111\/bcp.13510","journal-title":"Br J Clin Pharmacol"},{"key":"6603_CR52","doi-asserted-by":"publisher","unstructured":"Monaco F, Cicolin A (1999) Interactions between anticonvulsant and psychoactive drugs. Epilepsia 40. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb00888.x","DOI":"10.1111\/j.1528-1157.1999.tb00888.x"},{"key":"6603_CR54","volume-title":"Clinical pharmacokinetics","author":"JE Murphy","year":"2011","unstructured":"Murphy JE (2011) Clinical pharmacokinetics, 5th edn. ASHP, Bethesda, MD","edition":"5"},{"key":"6603_CR53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1345\/aph.1C413","volume":"37","author":"A Murphy","year":"2003","unstructured":"Murphy A, Wilbur K (2003) Phenytoin\u2013diazepam Interaction. Ann Pharmacother 37:659\u2013663. https:\/\/doi.org\/10.1345\/aph.1C413","journal-title":"Ann Pharmacother"},{"key":"6603_CR55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.tips.2009.07.002","volume":"30","author":"NN Nalivaeva","year":"2009","unstructured":"Nalivaeva NN, Belyaev ND, Turner AJ (2009) Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 30:509\u2013514. https:\/\/doi.org\/10.1016\/j.tips.2009.07.002","journal-title":"Trends Pharmacol Sci"},{"key":"6603_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0041-008X(85)90081-X","volume":"80","author":"H Nau","year":"1985","unstructured":"Nau H (1985) Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243\u2013250. https:\/\/doi.org\/10.1016\/0041-008X(85)90081-X","journal-title":"Toxicol Appl Pharmacol"},{"key":"6603_CR56","first-page":"291","volume":"40","author":"H Nau","year":"1990","unstructured":"Nau H (1990) Pharmacokinetic aspects of drug teratogenesis: species differences and structure activity relationships of the anticon-vulsant valproic acid. Acta Pharm Jugosl 40:291\u2013300","journal-title":"Acta Pharm Jugosl"},{"key":"6603_CR58","unstructured":"NHS Foundation Trust (2016) Medicines Information Bulletin; Vol. 14 No.; January 2016(v2): Valproate for bipolar disorder \u2013 formulary status reminder. https:\/\/www.oxfordhealthformulary.nhs.uk\/docs\/vol%2014%20no%201%20Valproate%20for%20bipolar%20disorder%20-%20formulary%20status%20reminder%202016v2.pdf"},{"key":"6603_CR59","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1192\/bjp.2019.137","volume":"215","author":"DC Owens","year":"2019","unstructured":"Owens DC (2019) Sodium valproate in psychiatric practice: time for a change in perception. Br J Psychiatry 215:516\u2013518. https:\/\/doi.org\/10.1192\/bjp.2019.137","journal-title":"Br J Psychiatry"},{"key":"6603_CR60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","volume":"27","author":"H-M Park","year":"2002","unstructured":"Park H-M, Kang S-S, Lee Y-B et al (2002) Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther 27:419\u2013425. https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00440.x","journal-title":"J Clin Pharm Ther"},{"key":"6603_CR61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","volume":"17","author":"E Perucca","year":"1984","unstructured":"Perucca E, Grimaldi R, Gatti G et al (1984) Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 17:665\u2013669. https:\/\/doi.org\/10.1111\/j.1365-2125.1984.tb02401.x","journal-title":"Br J Clin Pharmacol"},{"key":"6603_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40291-018-0335-y","volume":"22","author":"C Pisanu","year":"2018","unstructured":"Pisanu C, Heilbronner U, Squassina A (2018) The role of Pharmacogenomics in Bipolar Disorder: moving towards Precision Medicine. Mol Diagn Ther 22:409\u2013420. https:\/\/doi.org\/10.1007\/s40291-018-0335-y","journal-title":"Mol Diagn Ther"},{"key":"6603_CR63","doi-asserted-by":"publisher","unstructured":"Rakitin A (2020) Why do psychiatrists still prescribe valproate to women of childbearing potential? https:\/\/doi.org\/10.3389\/fpsyt.2020.00739. Front Psychiatry 11:","DOI":"10.3389\/fpsyt.2020.00739"},{"key":"6603_CR64","volume-title":"Use of licensed medicines for unlicensed applications in psychiatric practice","author":"Royal College of Psychiatrists Psychopharmacology Committee","year":"2017","unstructured":"Royal College of Psychiatrists Psychopharmacology Committee (2017) Use of licensed medicines for unlicensed applications in psychiatric practice, 2nd edn. The Royal College of Psychiatrists, London","edition":"2"},{"key":"6603_CR65","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jsps.2022.12.001","volume":"31","author":"A Safdar","year":"2023","unstructured":"Safdar A, Ismail F (2023) A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid. Saudi Pharm J 31:265\u2013278. https:\/\/doi.org\/10.1016\/j.jsps.2022.12.001","journal-title":"Saudi Pharm J"},{"key":"6603_CR66","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40261-017-0531-2","volume":"37","author":"G Sani","year":"2017","unstructured":"Sani G, Perugi G, Tondo L (2017) Treatment of bipolar disorder in a lifetime perspective: is Lithium still the best choice? Clin Drug Investig 37:713\u2013727. https:\/\/doi.org\/10.1007\/s40261-017-0531-2","journal-title":"Clin Drug Investig"},{"key":"6603_CR67","first-page":"325","volume":"146","author":"J Schnetzler","year":"1988","unstructured":"Schnetzler J, Pr\u00e9aubert G, Schnetzler F (1988) A valproic acid-diazepam combination as an alternative to neuroleptic treatment. Ann Med Psychol (Paris) 146:325\u2013339","journal-title":"Ann Med Psychol (Paris)"},{"key":"6603_CR68","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0004867416664794","volume":"51","author":"S Sportiche","year":"2017","unstructured":"Sportiche S, Geoffroy PA, Brichant-Petitjean C et al (2017) Clinical factors associated with lithium response in bipolar disorders. Australian New Z J Psychiatry 51:524\u2013530. https:\/\/doi.org\/10.1177\/0004867416664794","journal-title":"Australian New Z J Psychiatry"},{"key":"6603_CR69","doi-asserted-by":"crossref","unstructured":"Stahl SM (2018) Prescriber\u2019s guide \u2013 children and adolescents. Cambridge University Press","DOI":"10.1017\/9781108561402"},{"key":"6603_CR70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0163-8343(97)00129-1","volume":"20","author":"A Stoudemire","year":"1998","unstructured":"Stoudemire A (1998) Lithium intolerance in a Medical-Psychiatric Population. Gen Hosp Psychiatry 20:85\u201390. https:\/\/doi.org\/10.1016\/S0163-8343(97)00129-1","journal-title":"Gen Hosp Psychiatry"},{"key":"6603_CR71","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/hup.1073","volume":"24","author":"T Suzuki","year":"2009","unstructured":"Suzuki T, Uchida H, Takeuchi H et al (2009) Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacology: Clin Experimental 24:628\u2013638. https:\/\/doi.org\/10.1002\/hup.1073","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"key":"6603_CR72","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","volume":"112","author":"L Tan","year":"2010","unstructured":"Tan L, Yu J-T, Sun Y-P et al (2010) The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 112:320\u2013323. https:\/\/doi.org\/10.1016\/j.clineuro.2010.01.002","journal-title":"Clin Neurol Neurosurg"},{"key":"6603_CR73","unstructured":"The Pharmaceutical Society of Israel (2023) Depalept 500 enteric coated tablets. In: https:\/\/drug.co.il\/drugs\/\u05d3\u05e4\u05dc\u05e4\u05d8-500-\u05d8\u05d1\u05dc\u05d9\u05d5\u05ea-\u05de\u05e6\u05d5\u05e4\u05d5\u05ea\/"},{"key":"6603_CR74","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jfma.2020.09.004","volume":"120","author":"Y-J Tseng","year":"2021","unstructured":"Tseng Y-J, Huang S-Y, Kuo C-H et al (2021) Factors to influence the accuracy of albumin adjusted free valproic acid concentration. J Formos Med Assoc 120:1114\u20131120. https:\/\/doi.org\/10.1016\/j.jfma.2020.09.004","journal-title":"J Formos Med Assoc"},{"key":"6603_CR75","doi-asserted-by":"publisher","first-page":"e0272622","DOI":"10.1371\/journal.pone.0272622","volume":"17","author":"M Usman","year":"2022","unstructured":"Usman M, Shaukat Q-A, Khokhar MI et al (2022) Comparative pharmacokinetics of valproic acid among Pakistani and South Korean patients: a population pharmacokinetic study. PLoS ONE 17:e0272622. https:\/\/doi.org\/10.1371\/journal.pone.0272622","journal-title":"PLoS ONE"},{"key":"6603_CR76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/2045125311405566","volume":"1","author":"S Varma","year":"2011","unstructured":"Varma S, Bishara D, Besag FMC, Taylor D (2011) Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 1:47\u201366. https:\/\/doi.org\/10.1177\/2045125311405566","journal-title":"Ther Adv Psychopharmacol"},{"key":"6603_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s002130000380","volume":"150","author":"K Vasudev","year":"2000","unstructured":"Vasudev K, Goswami U, Kohli K (2000) Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 150:15\u201323. https:\/\/doi.org\/10.1007\/s002130000380","journal-title":"Psychopharmacology"},{"key":"6603_CR78","doi-asserted-by":"publisher","first-page":"23150","DOI":"10.1038\/s41598-021-02628-x","volume":"11","author":"S Wang","year":"2021","unstructured":"Wang S, Li J, Song M et al (2021a) Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia. Sci Rep 11:23150. https:\/\/doi.org\/10.1038\/s41598-021-02628-x","journal-title":"Sci Rep"},{"key":"6603_CR79","doi-asserted-by":"publisher","first-page":"23150","DOI":"10.1038\/s41598-021-02628-x","volume":"11","author":"S Wang","year":"2021","unstructured":"Wang S, Li J, Song M et al (2021b) Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia. Sci Rep 11:23150. https:\/\/doi.org\/10.1038\/s41598-021-02628-x","journal-title":"Sci Rep"},{"key":"6603_CR80","volume-title":"Basic Clinical Pharmacokinetics","author":"ME Winter","year":"2010","unstructured":"Winter ME (2010) Basic Clinical Pharmacokinetics, 5th edn. Lippincott Williams & Wilkins Health, Philadelphia, PA","edition":"5"},{"key":"6603_CR81","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/10401239309148967","volume":"5","author":"OM Wolkowitz","year":"1993","unstructured":"Wolkowitz OM (1993) Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 5:79\u201380","journal-title":"Ann Clin Psychiatry"},{"key":"6603_CR83","doi-asserted-by":"crossref","unstructured":"Wood SN (2017) Generalized additive models. Chapman and Hall\/CRC","DOI":"10.1201\/9781315370279"},{"key":"6603_CR82","unstructured":"Wood S (2023) Package \u2018mgcv\u2019; R package version 1.9-0"},{"key":"6603_CR84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV et al (2018) Canadian Network for Mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20:97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609","journal-title":"Bipolar Disord"},{"key":"6603_CR85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","volume":"15","author":"G Zaccara","year":"1988","unstructured":"Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of Valproic acid \u2013\u20091988. Clin Pharmacokinet 15:367\u2013389. https:\/\/doi.org\/10.2165\/00003088-198815060-00002","journal-title":"Clin Pharmacokinet"},{"key":"6603_CR86","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00228-021-03246-2","volume":"78","author":"Y-N Zang","year":"2022","unstructured":"Zang Y-N, Guo W, Niu M-X et al (2022) Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder. Eur J Clin Pharmacol 78:405\u2013418. https:\/\/doi.org\/10.1007\/s00228-021-03246-2","journal-title":"Eur J Clin Pharmacol"},{"key":"6603_CR87","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/jhg.2017.91","volume":"62","author":"M-M Zhu","year":"2017","unstructured":"Zhu M-M, Li H-L, Shi L-H et al (2017) The pharmacogenomics of valproic acid. J Hum Genet 62:1009\u20131014. https:\/\/doi.org\/10.1038\/jhg.2017.91","journal-title":"J Hum Genet"},{"key":"6603_CR88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","volume":"23","author":"M Zink","year":"2010","unstructured":"Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23:103\u2013111. https:\/\/doi.org\/10.1097\/YCO.0b013e3283366427","journal-title":"Curr Opin Psychiatry"},{"key":"6603_CR89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1753-2000-2-24","volume":"2","author":"JM Zito","year":"2008","unstructured":"Zito JM, Derivan AT, Kratochvil CJ et al (2008) Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2:24. https:\/\/doi.org\/10.1186\/1753-2000-2-24","journal-title":"Child Adolesc Psychiatry Ment Health"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06603-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:31:29Z","timestamp":1724401889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06603-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":89,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["6603"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06603-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Geha Mental Health Center Institutional Review Board (IRB; protocol number 0007-21-GEH, date of approval June 16th, 2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the manuscript, providing their consent for its publication in its current form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}